Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment o…
| Métrica | ADXN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | 72.9% | -39.2% | +112.1% |
| ROA | 66.1% | -30.9% | +97.0% |
| Current Ratio | 4.42 | 2.73 | +1.69 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 66.1% | — |
| ✗Flujo de caja operativo positivo | −CHF 5M | −CHF 8M |
| ✓Rentabilidad sobre activos al alza | 66.1% | -227.4% |
| ✗Caja operativa/activos supera al ROA | -50.3% | ROA 66.1% |
| ✗Menos deuda a largo plazo | 0.0% | 0.0% |
| ✓Mejor liquidez (ratio corriente) | 4.42 | 1.46 |
| ✗Sin aumentar el nº de acciones | 98M | 74M |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | — | 0.35 |
| Calidad del negocio | FY24 |
|---|---|
| ✗ROCE > 10 % | -27.9% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
Addex Therapeutics Ltd. cotiza a 2.76 USD y tiene una capitalización bursátil de $5M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud